About this course

Learning Objectives

• Describe the typical course of ADHD and list the full range of adverse outcomes
• List the strengths and weaknesses of first-line treatments
• Discuss the strengths and weaknesses of second line treatments
• Identify the key components of diagnosis of ADHD in children and adults.
• Differentiate how ADHD may present by gender and age.
• Describe common comorbidities associated with ADHD

Learning Levels

• Beginner

Target Audience

Course Instructor(s)

• 

  Ryan Landoll, PhD

  Dr. Landoll has successfully treated patients struggling with anxiety, depression, trauma, disruptive behavior, sleep difficulties, chronic pain, grief, and other health related conditions. He has worked extensively with both children and adults, including military families, active-duty service members, and veterans, along with individuals challenged by interpersonal, occupational, and relationship issues. He is trained in a wide range of evidenced-based treatments, including Cognitive Behavioral Therapy (CBT), Interpersonal Therapy for Depression (IPT), Cognitive Behavioral Therapy for Insomnia (CBT-i), Acceptance and Commitment Therapy (ACT), Cognitive Processing Therapy (CPT) for Post-traumatic Stress Disorder (PTSD), Prolonged Exposure Therapy (PE) for PTSD, and the Unified Protocol for the Treatment of Emotional Disorders in Children and Adolescents (UP-C/A). Dr. Landoll is also available for parent consultations, offering support to parents in navigating a child's developmental transitions and collaborative problem solving for healthy parenting and optimal child development.

• 

  Daniel Pine, MD

  Psychiatrist

  Practice Philosophy: Daniel S. Pine, MD, is a psychiatrist specializing in the treatment of anxiety and mood disorders in children and adolescents. He is widely acknowledged as one of the world’s top anxiety researchers, and applies his extensive knowledge through diagnosis and treatment of young patients at The Ross Center. Families value the clinical expertise he provides through psychiatric assessment of mood, anxiety, and behavioral disorders, and his medical acumen in prescribing medications that take into consideration a child’s age, diagnosis, symptom duration and severity. He is often sought out by parents and families for clinical consultations in more complex cases, and can provide second opinions diagnostically for those who have struggled for answers. When appropriate, he collaborates with a child’s therapist and other providers to help insure consistent delivery of care. Families appreciate his sensitivity and compassion, and benefit from his vast understanding of the biology behind the mind of an anxious child.

  Areas of Expertise: Dr. Pine is a renowned expert in the field of pediatric mental health. His background in research has led to greater understanding of the biological roots of psychiatric disorders. He is a leader in the development of diagnostic tools and treatments for childhood psychiatric disorders. As a clinician, he uses this wealth of experience to successfully treat anxiety, mood, and behavioral disorders in children and adolescents.

  Experience and Training: Dr. Pine also serves at the National Institute of Mental Health (NIMH) as the Chief Psychiatrist, Section on Development and Affective Neuroscience, in the Intramural Research Program. He received his medical degree from the University of Chicago, and spent 10 years at Columbia University’s College of Physicians and Surgeons in training and research on child psychiatry. His research has focused on the epidemiology, biology, and treatment of pediatric mental illnesses, and is featured in over 500 published scientific papers. Additionally, Dr. Pine has chaired the Food and Drug Administration’s Psychopharmacology Drug Advisory Board. His many honors include the Blanche Ittelson Award from the American Psychiatric Association for outstanding research contributions to the field of child psychiatry.

References

• Harstad, E., Shults, J., Barbaresi, W., Bax, A., Cacia, J., Deavenport-Saman, A., Friedman, S., LaRosa, A., Loe, I. M., Mittal, S., Tulio, S., Vanderbilt, D., & Blum, N. J. (2021). Α₂-adrenergic agonists or stimulants for preschool-age children with attention-deficit/hyperactivity disorder. JAMA, 325(20), 2067. https://doi.org/10.1001/jama.2021.6118
• Lam, S.-L., Criaud, M., Lukito, S., Westwood, S. J., Agbedjro, D., Kowalczyk, O. S., Curran, S., Barret, N., Abbott, C., Liang, H., Simonoff, E., Barker, G. J., Giampietro, V., & Rubia, K. (2022). Double-blind, sham-controlled randomized trial testing the efficacy of fmri neurofeedback on clinical and cognitive measures in children with ADHD. American Journal of Psychiatry, 179(12), 947–958. https://doi.org/10.1176/appi.ajp.21100999
• Sibley, M. H., Arnold, L. E., Swanson, J. M., Hechtman, L. T., Kennedy, T. M., Owens, E., Molina, B. S. G., Jensen, P. S., Hinshaw, S. P., Roy, A., Chronis-Tuscano, A., Newcorn, J. H., & Rohde, L. A. (2022). Variable patterns of remission from ADHD in the multimodal treatment study of ADHD. American Journal of Psychiatry, 179(2), 142–151. https://doi.org/10.1176/appi.ajp.2021.21010032
• Ferguson, H. J., Brunsdon, V. E., & Bradford, E. E. (2021). The developmental trajectories of executive function from adolescence to old age. Scientific Reports, 11(1). https://doi.org/10.1038/s41598-020-80866-1
• Gair, S. L., Brown, H. R., Kang, S., Grabell, A. S., & Harvey, E. A. (2021). Early development of comorbidity between symptoms of ADHD and anxiety. Research on Child and Adolescent Psychopathology, 49(3), 311–323. https://doi.org/10.1007/s10802-020- 00724-6
• Winders Davis, D., Jawad, K., Feygin, Y., Creel, L., Kong, M., Sun, J., Lohr, W. D., Williams, P. G., Le, J., Jones, V. F., Trace, M., & Pasquenza, N. (2021). Disparities in ADHD diagnosis and treatment by race/ethnicity in youth receiving Kentucky medicaid in 2017. Ethnicity & Disease, 31(1), 67–76. https://doi.org/10.18865/ed.31.1.67